Core Viewpoint - The CSI Hong Kong Stock Connect Biotechnology Theme Index has shown significant growth, with a 5.26% increase over the past month, 20.82% over the past three months, and 25.29% year-to-date, reflecting strong performance in the biotechnology sector [1]. Group 1: Index Performance - The CSI Hong Kong Stock Connect Biotechnology Theme Index is currently at 1183.16 points, having been established with a base date of December 28, 2018, at 1000.0 points [1]. - The index comprises 50 listed companies involved in biopharmaceuticals, pharmaceuticals, and biotechnology services, selected from the Hong Kong Stock Connect range [1]. Group 2: Index Holdings - The top ten weighted companies in the index include: BeiGene (14.31%), WuXi Biologics (12.72%), Innovent Biologics (10.78%), CanSino Biologics (7.78%), CSPC Pharmaceutical Group (6.03%), China Biologic Products (5.8%), Hansoh Pharmaceutical (3.57%), Kelun-Biotech (3.31%), Zai Lab (3.29%), and WuXi AppTec (3.23%) [1]. - The index is fully composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [1]. Group 3: Industry Composition - The industry composition of the index holdings is as follows: biopharmaceuticals account for 50.37%, chemical drugs for 25.76%, pharmaceutical and biotechnology services for 20.60%, and medical devices for 3.27% [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December, with a sample adjustment limit of 20% [2].
中证港股通生物科技主题指数报1183.16点，前十大权重包含信达生物等